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Recently, several systems designed to trigger RNA interference by
using small hairpin RNA driven by polymerase III promoters have
been described. Here, we report a lentiviral-mediated small inter-
fering RNA delivery system that can be induced by CRE recombi-
nase. The system consists of a lentiviral vector carrying a mouse U6
promoter that is separated from a small hairpin RNA by a random
DNA stuffer sequence flanked by modified loxP sites. The silencing
cassette is not expressed until activated by addition of CRE recom-
binase delivered by a lentiviral vector. We have used this system
to show specific down-regulation of GFP and two endogenous
genes (the tumor suppressor p53 and the NF-B transcription factor
subunit p65) in vitro. Furthermore, down-regulation of both p53
and p65 resulted in the expected effect on downstream genes and
cellular phenotype. We foresee multiple applications of this system
both in vitro and in vivo to down-regulate specific targets in a
tissue-specific and localized manner.
In the postgenomic era, one of the pressing biological questions ishow to decipher the function of myriad unknown genes. Gene
knockout by homologous recombination has become the mainstay
of understanding gene function. In mouse, perhaps one of the most
successful mammalian model systems, gene knockout technology
has been a powerful tool of dissecting gene function, but it is
laborious and expensive. This technology has been less used for in
vitro studies because all of the alleles need to be knocked out, so
researchers have taken advantage of antisense and ribozyme tech-
nology, which are not always reliable or robust. RNA interference
(RNAi) has emerged as a pathway that offers great hope and
promise to study the functions of a vast number of genes (1–14). In
invertebrates, long double-stranded RNA molecules are processed
by the endonuclease Dicer into 21- to 23-nucleotide small inter-
fering RNAs (siRNAs), which are then incorporated into an
RNA-induced silencing complex, a multicomponent nuclease com-
plex that selects and degrades mRNAs that are homologous to the
initially delivered double-stranded RNA (15, 16). However, in
mammalian systems, introduction of long double-stranded RNA
(50 bp) results in systemic, nonspecific inhibition of translation
due to activation of the double-stranded RNA-dependent protein
kinase R (PKR) response. This problem can be solved by the use
of synthetic siRNA (30 bp) that can be delivered either exog-
enously (17) or expressed endogenously from RNA polymerase pol
III promoters, resulting in a powerful tool for achieving specific
down-regulation of target mRNAs (11, 12, 18, 19). Currently, in
mammalian systems, the method of choice to generate a whole-
genome knockdown screening by using RNAi is to systematically
generate synthetic or pol III transcribed siRNA hairpins for every
known target gene. Algorithms have been developed to predict
effective siRNA sequences for efficient screening of large numbers
of genes (20).
We have shown that the lentiviral vector system can express
integrated siRNA efficiently in a wide variety of cell lines,
tissues, and even preimplantation embryos (14). More interest-
ingly, we and others (7) have reported that the resulting progeny
expressing siRNA had reduced expression of a specific gene. We
now want to extend the use of lentiviral siRNA transgenesis
further by generating regulatable siRNA vectors. We chose to
use a loxP–CRE system because it has extensively been used to
generate conditional knockout mice. Furthermore, many inves-
tigators have generated cell or tissue-specific CRE mice. Here,
we report the design and construction of lentiviral siRNA vectors
capable of suppressing GFP, p53, and p65 expression only upon
expression of CRE recombinase.
Methods
Primer Design. The following primers (5 to 3) were used































CGAAGTTATT; and R10, GGAAGGTCCGCTGGATTGA.
Note that R2 contains the siRNA hairpin against GFP orig-
inally published by Brummelkamp et al. (12); R8 contains the
siRNA hairpin against mouse p53 originally published by Dirac
and Bernards (21). The pol III termination signal is underlined,
the sense and antisense strands of the GFP hairpin are in
lowercase, and the loop is italicized. TATA box sequences are
shown in bold, with loxP spacer mutations in bold italics.
The following siRNA targets were used in this study: GFP,
Abbreviations: mU6, mouse U6; shRNA, small hairpin RNA; siRNA, small interfering RNA;
pol, polymerase; PSE, proximal sequence element; moi, multiplicity of infection; PGTE,
PGEM-T Easy.
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GCTCCTGAAC; and p53, GTACATGTGTAATAGCTCC.
Construct Design. Cloning of LV-shGFP-WT. The mouse U6 (mU6)
promoter (GenBank accession no. X06980) was amplified by
PCR from mouse genomic DNA using primers F1and R1 and
cloned into pGEM-T Easy (PGTE) (Promega), creating
PGTEmU6-WT. This clone was used as template for gener-
ation of an mU6-shGFP-WT PCR product with a 5 end ClaI site
and a 3 end SalI site by PCR with primers F2 and R2, which was
cloned first into PGTE (creating PGTEmU6-shGFP-WT) and
then into the fourth-generation lentivector (LV#5, described in
ref. 22) digested with ClaI–SalI (Fig. 1A).
Cloning of LV-shGFP-ON. The sequence of the mU6 promoter was
modified to introduce (i) a XhoI site between 69 and 72, (ii)
a modified loxP site (loxP*) (ATAACTTCGTATAGTATAAAT-
TATACGAAGTTAT) between 11 and 44 (with the spacer
sequence mutated from GCATACAT to GTATAAAT and engi-
neered to conserve the original TATA box position, 24 to
30), and (iii) a HindIII site between5 and10. This was done
by nested PCR, using PGTEmU6-shGFP-WT as template with
F2 as forward primer and reverse primers R3 and R4. The
resulting PCR product was cloned into PGTE (creating
PGTEmU6-ON). This cloning step eliminated the short hair-
pin GFP (shGFP) hairpin, which was reintroduced by annealing
primers F3 and R5 and cloning the resulting product into
PGTEmU6-ON digested with HindIII and NcoI, creating
PGTEmU6-shGFP-ON. The ClaI–SalI mU6-shGFP-ON frag-
ment was cloned into LV#5 cut with ClaI–SalI (Fig. 1C).
Cloning of LV-shRNA-OFF. PGTEmU6-shGFP-ON was modified
further by introducing a sequence containing a second loxP* site
preceded by BamHI and XbaI sites. This was achieved by
annealing primers F4 and R6, followed by cloning of the resulting
reannealed product into a unique HindIII site in PGTEmU6-
shGFP-ON. A clone in the correct orientation (with the BamHI
and XbaI sites between the two loxP* sites, PGTEmU6-loxP*-
loxP*shGFP) was then modified by introducing a stuffer frag-
ment (S) consisting of 1 kb of LacZ fragment generated by PCR
from pcDNA 3.1 His-myc LacZ (Invitrogen) using primers F5
and R7 (F5 contains a pol III termination signal near the 5 end)
by cloning into the BamHI and XbaI sites, generating
PGTEmU6-shGFP-OFF (Fig. 1B).
Cloning of LV-shp53-OFF or LV-shp65-OFF. PGTEmU6-shGFP-OFF
was cut with XbaI–NcoI, and the XbaI–NcoI insert was replaced
with annealed primers F6 and R8 (p53) or F7 and R9 (p65),
generating PGTEmU6-shp53-OFF and PGTEmU6-shp65-
OFF, respectively. A sequence for shp65 was not available in the
literature; thus, we cloned six shp65 candidates into PEU6
(Invitrogen) and tested their silencing capability by cotransfec-
tion of each candidate with a p65–GFP fusion expression vector
in 293T cells (data not shown). The ClaI–SalI mU6-shRNA-OFF
fragments were cloned into LV#5 cut with ClaI–SalI, as de-
scribed above.
Cloning of LV-shRNA-WTGFP. LV#5 was modified by introducing a
Gateway destination cassette consisting of attR1-CmR-ccdB-
attR2 into a unique HpaI site in LV#5, thus adapting it to
Gateway cloning technology (Invitrogen) (Fig. 1D). Small hair-
pin RNA (shRNA) hairpins for p53 and p65 were cloned into
PEU6 entry vector (Invitrogen) and transferred by an LR
clonase reaction into LV-shRNA-WTGFP according to man-
ufacturer’s protocol.
Cell Culture and Reagents. GFP-expressing 293T cells were cul-
tured in DMEM plus 10% FBS (HyClone). Spontaneously
immortalized murine embryo fibroblasts were cultured in
DMEM supplemented with 10% FCS (HyClone)100 g/ml
penicillin100 g/ml streptomycin250 ng/ml of amphotericin B
(GIBCO). Doxorubicin was purchased from Sigma and dissolved
Fig. 1. Diagram of lentiviral constructs (integrated proviral form) used in this study. (A) LV-shGFP-WT: lentiviral vector carrying a wild-type silencing cassette.
The mU6 promoter consists of three elements: distal sequence element, PSE, and TATA box. The circled numbers (1, 2, and 3) indicate sites where unsuccessful
attempts were made to introduce loxP sites. (B) LV-shRNA-OFF: the introduction of a DNA stuffer sequence (LacZ) flanked by modified loxP sites (loxP*). loxP*
is a loxP site containing two mutations in the 8-bp spacer region (GCATACAT to GTATAAA), resulting in a modified loxP site (loxP*) with a spacer that resembles
a U6 TATA box. The presence of a stuffer fragment puts the promoter in an OFF configuration. The promoter will be silent until CRE recombinase excises the
fragment, leaving one loxP* site (LV-shRNA-ON) (C) and switching the silencing cassette from OFF to ON. The shRNA is thus expressed, leading to siRNA synthesis
and target shutdown. (D) LV-shRNAGFP: lentiviral construct allowing the delivery of both a silencing cassette and a GFP marker. PPT, polypyrimidine tract;
WPRE, woodchuck hepatitis virus posttranscriptional response element; all viral elements are shown on a white background; DSE, distal sequence element; TATA,
mU6 TATA box; loxP*, modified loxP site with spacer resembling mU6 TATA box; all mU6 promoter elements are shown on a violet background, except for T5
(pol III transcription termination signal), which is shown on a red background. The stuffer fragment (randomly chosen 1-kb region of LacZ) is shown on a yellow
background and is present only in LV-shRNA-OFF. The GFP marker in LV-shRNA is shown on a green background. shRNA hairpins are shown in black.
7348  www.pnas.orgcgidoi10.1073pnas.0402107101 Tiscornia et al.
in Milli-Q water at a concentration of 10 mgml as stock. Tumor
necrosis factor  was obtained from Calbiochem and stored in
PBS containing 0.1% BSA. The antibodies against p65 (C-20),
IB (C-21), IB (C-20), p50 (NLS), p21 (C-19), and p53
(FL-393)-G were all obtained from Santa Cruz Biotechnology.
Anti- actin antibody (Sigma) was used to detect levels of actin,
which served as loading controls in all of the experiments. The
levels of mdm2 were determined by using the Ab-2 from
Oncogene Research Products.
Viral Production and Transduction. Viral Production was done as
described (22, 23). Briefly, 293T cells were transfected by the CaCl2
precipitation method. Supernatants were collected 48 and 72 h after
transfection, filtered, and concentrated by two successive ultracen-
trifugations. Viral preparation titers were determined by p24
ELISA (Alliance; NEN) and by TaqMan real-time PCR determi-
nation of transduced proviral genomes using primers F8 and R10
for woodchuck hepatitis virus posttranscriptional response element.
On average, the vector preparations were 1.5 E4 particles per
nanogram of p24 (see below). In vitro transduction was done by
plating cells on 24-well plates pretreated with 0.002% poly(L-lysine)
in PBS. After overnight culture in DMEM plus 10% FBS, viral
preparation aliquots were diluted to achieve the estimated range of
multiplicity of infection (moi) required to test our vectors, and
infection was carried out in a 200-l total volume. After 24 h, cells
were washed with PBS, and fresh medium was added. Cells were
cultured and passaged for 5 days (p53 and p65) or 9 days (GFP).
Assays. GFP levels were determined by fluorescence-activated cell
sorting (FACS) (Becton Dickinson).
Western blots. Typically, cells were cultured in six-well dishes. To
detect p65, IB, IB, and p50 proteins, whole-cell extracts of
confluent cells were prepared by lysis in radioimmunoprecipitation
assay (RIPA) buffer, and these lysates were resolved on Bis-Tris
SDS gels (4–12%) in Mops buffer (Invitrogen). To analyze the
levels of p53 and its target genes, cells were either left untreated or
treated with 0.4 gml doxorubicin for 12–14 h when indicated,
washed with PBS, and harvested in 2 SDS loading buffer. After
electrophoresis on 10% Tris glycine gels, proteins were transferred
on poly(vinylidene difluoride) membrane (Immobilon P, Milli-
pore). All membranes were blocked in PBS without Mg2 and Ca2
containing 0.2% Tween 20 and 5% nonfat milk and probed with the
indicated antibodies in PBS without Mg2 and Ca2 containing
0.2% Tween 20 and 1% milk (24).
Cell-survival assays. Cells typically were plated in 12-well dishes.
Confluent murine embryo fibroblasts infected with LV-CRE
(control), LV-shp65, and LV-shp65-OFF were either left un-
treated or were treated with fresh 100 ngml tumor necrosis
factor  for 3 consecutive days. Surviving cells were estimated by
staining with crystal violet and reading the stain leached in
methanol at 595 nm by using a spectrophotometer. The un-
treated samples in each cell population were considered as 100%
survival and were used to calculate the percentage of survival.
TaqMan PCR. Primer sets used for quantitative TaqMan PCR to
detect proviral DNA were F8 and R10 for woodchuck hepatitis
virus posttranscriptional response element. Reactions contained
TaqMan universal mastermix (Perkin–Elmer), 300 nM each
primer, 100 nM probe, and a 100-ng template. Reactions were
analyzed by using the ABI Prism 7700 sequence detection system
(Applied Biosystems) using the following PCR cycles: 2 min at
50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C, and 1 min at 60°C.
To analyze the proviral DNA content of the samples, a standard
curve ranging from 10 to 1  106 copies was measured in every
experiment. All samples and standards were analyzed in triplicate.
Results and Discussion
We have designed a system that consists of a lentiviral vector
carrying mU6 that is separated from a shRNA by a random DNA
stuffer sequence flanked by modified loxP sites. The expression
cassette is silent until activated by addition of CRE recombinase
delivered by a lentiviral vector.
The general structure of a lentiviral vector carrying a silencing
cassette consisting of mU6 driving an shRNA hairpin targeting
GFP is shown in Fig. 1A. To engineer a vector that would only be
Fig. 2. (A) 293T cells expressing two copies of GFP were infected with different lentiviral constructs, with mois as shown in B. Vector titers were determined
by p24 ELISA and by TaqMan real-time PCR determination of transduced proviral genomes. On average, the vector preparations were 1.5 E4 particles per
nanogram of p24. Cells were cultured for 9 days, and GFP expression levels were quantitated by FACS analysis. GFP expression levels were unaffected by infection
with LV-CRE alone (Aa). Infection with LV-shGFP-OFF in the absence of LV-CRE resulted in no change in GFP levels (Ab), whereas LV-shGFP-WT and LV-shGFP-ON
were equally effective in down-regulating the target (A c and d). Coinfection of LV-CRE (moi  70) and LV-shGFP-OFF (moi  100) resulted in efficient
down-regulation of GFP expression (Ae). (B) FACS analysis composite. Coinfection of LV-CRE (moi 70) with decreasing mois of LV-siGFP-OFF (moi 60, 20, or
10) resulted in decreased silencing of GFP (data not shown). Similarly, decreasing of LV-CRE (moi 70, 35, 7, and 3) while keeping LV-shGFP-OFF constant (moi
100) diminished silencing (data not shown).






active after expression of CRE recombinase, we sought to design an
inactive cassette in which the mU6 promoter is separated from the
shRNA hairpin by a stuffer fragment flanked by loxP sites. The
stuffer fragment should contain a pol III termination signal (25)
near its 5 end to ensure the promoter is silent. Delivery of CRE
recombinase would result in excision of the intervening sequence,
thus allowing the promoter to drive expression of the shRNA
hairpin and down-regulation of the target. Whereas the general
strategy is straightforward, the fact that CRE recombinase-
mediated excision of a loxP flanked sequence leaves a loxP site at
the excision site posed the problem of finding a site in the silencing
cassette where the leftover loxP site would not interfere with
efficient expression and processing of the shRNA hairpin. LoxP
sites are 34-bp long and consist of two inverted repeats of 13 bp
separated by a spacer fragment of 8 bp (26). The mU6 promoter
consists of the distal sequence element, the proximal sequence
element (PSE), and a TATA box (TATA) (27–29). Three potential
sites in an mU6-shGFP silencing cassette, namely (i) between the
distal sequence element and the PSE, (ii) between the transcrip-
tional start site and the shRNA hairpin, and (iii) within the shRNA
hairpin loop, were tested to determine the effect of a loxP site in the
mU6 promoter on silencing of GFP (Fig. 1A). All three positions
were found to be unsuitable (data not shown), but interestingly, a
recent report (see ref. 35) obtained CRE-inducible RNA interfer-
ence by positioning an intervening sequence within the shRNA
loop, suggesting that the small differences in DNA stuffer design
may have considerable effects on the efficiency of inducibility or
down-regulation of the target mRNA. Furthermore, the PSE,
TATA box, and transcriptional start site are separated by 17 and 24
bp, respectively; the arrangement of these elements is compact, and
expression of the promoter is extremely sensitive to alterations in
the spacing between them (29). Thus, positioning the 34-bp loxP site
either between the PSE and the TATA box or between the TATA
box and the transcriptional start site was not deemed suitable. We
therefore took advantage of the similarity of the loxP 8-bp spacer
sequence (GCATACAT) and the mU6 TATA box (TATAAA),
noting that mutating the first and second C bases of the spacer to
T and A, respectively, created a mutant loxP site (referred to as
loxP*), whose 8-bp spacer region resembles a mU6 TATA box. A
published report examined the effect of a large number of single
and double-base substitutions in the spacer sequence of loxP and
found that mutations in this region of the loxP site had varied effects
on the efficiency of CRE-mediated recombination. Interestingly,
this particular double mutant (loxP*) resulted in a loxP site capable
of recombination, albeit at a frequency of35% of wild-type loxP
levels (30). We surmised that any loss of recombination efficiency
could be compensated for by increasing viral moi, and therefore, we
designed the two following lentiviral constructs driving a shRNA
against GFP: (i) a silencing cassette in the ON configuration, i.e.,
an mU6 promoter containing a loxP* site between the PSE and the
transcriptional start site (LV-shGFP-ON, Fig. 1C), and (ii) a
silencing cassette in the OFF configuration, i.e., an mU6 promoter
containing an intervening sequence flanked by loxP* sites between
the PSE and the transcriptional start site (LV-shGFP-OFF, Fig.
1B). We arbitrarily chose a 1-kb fragment of the LacZ ORF to use
as a stuffer sequence and introduced a pol III termination signal
(TTTTT) near the 5 end. These lentiviral vectors were used to
infect a 293T cell line stably expressing two copies of GFP.
Quantification of GFP expression was carried out by FACS analysis
9 days after infection. LV-CRE alone (moi 70) had no effect on
GFP expression levels (Fig. 2Aa). As expected, although the
LV-shGFP-OFF (moi 100) was incapable of shutting down GFP
expression, the LV-shGFP-ON (moi 100) was as efficient as the
LV-shGFP-WT (moi 100) in reducing GFP levels to5% of the
levels found in uninfected cells (Fig. 2A b–d). To test how efficiently
coexpression of CRE recombinase could switch the silencing
cassette from OFF to ON, we coinfected the GFP-expressing 293T
cell line with LV-shGFP-OFF (moi  100) and LV-CRE (moi 
70), a CRE recombinase expressing self-deleting lentiviral vector
described in ref. 31. Use of this self-deleting vector allowed us to
express CRE transiently, avoiding potential toxicity problems (31,
32). Cells infected with LV-CRE (moi  70) expressed CRE
recombinase within 24 h, with a peak of expression 48 h after
infection; CRE recombinase levels decreased thereafter and were
almost undetectable beyond 96 h after infection (data not shown).
Infection of LV-CRE at higher mois resulted in visible toxicity to
the cells (data not shown). Remarkably, coinfection of LV-shiGFP-
OFF (moi  100) and LV-CRE (moi  70) resulted in down-
regulation of GFP to levels similar to those seen in cells infected
with the LV-shGFP-ON alone (moi 100), indicating that expres-
sion of CRE recombinase efficiently excised the stuffer fragment
Fig. 3. Regulated knockdown of endogenous genes. (A) Wild-type murine
embryo fibroblasts (MEFs) were infected with mois of 50 (lane 3), 100 (lane 4),
200 (lane 5), and 400 (lanes 6 and 7) of LV-shp65-OFF, with (lanes 3–6) or
without (lane 7) coinfection with LV-CRE at an moi of 700. Cells were cultured
for 5 days, and lysates were analyzed for the indicated markers by Western
blot analysis. LV-shp65-OFF used in combination with LV-CRE (but not when
used alone) resulted in highly decreased levels of p65 and downstream
targets. Actin was used as a loading control, and p50 and a nonspecific band
(NS) are included to show specificity. (B) Tumor necrosis factor -induced
apoptosis. MEFs infected with LV-shp65-WTGFP (moi 600) were used as a
positive control (lane 2), and LV-shp65-OFF (moi  400) in combination with
LV-CRE (moi  700) showed increased sensitivity to apoptosis after being
assayed as described in Methods. (C) Wild-type MEFs were infected with mois
of 25 (lane 4), 125 (lane 5), 250 (lane 6), and 500 (lanes 7 and 8) of LV-shp53-
OFF, with (lanes 4–7) or without (lane 8) coinfection with LV-CRE at moi 700.
Cells were cultured for 5 days and either left untreated (lane 1) or treated with
0.4 gml doxorubicin (lanes 2–8) and assayed by Western blotting. Cells
infected with LV-shp53-WTGFP (moi  600, lane 3) were used as a positive
control. Increased mois of LV-shp53-OFF (moi  500) in combination with
LV-CRE (moi 700) resulted in increasingly stronger down-regulation of p53
and downstream targets (lanes 4–7). Actin was used as a loading control, and
a nonspecific band is included to show specificity.
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and resulted in activation of the GFP silencing cassette (Fig. 2Ae).
To quantitate the silencing power of the system, we titrated down
levels of LV-shGFP-OFF (moi  60, 20, or 10) while maintaining
the same levels of infection for LV-CRE (moi 70). This resulted
in increasingly lower levels of silencing of the target; under the
conditions of this assay, a minimum LV-shGFP-OFF moi of 60 was
required to obtain satisfactory silencing of GFP. Conversely, low-
ering the moi of LV-CRE below 70 (moi  35, 7, and 3) also
resulted in increasingly lower levels of silencing of GFP expression
(Fig. 2B, bars f–k). Representative results of composite FACS
analysis are summarized in Fig. 2B. We conclude that the levels of
expression of presumably any given target gene for which an
effective shRNA is available can be controlled by careful titration
of LV-shRNA-OFF and LV-CRE. It is thus possible that expres-
sion of CRE under the control of tissue-specific promoters can
regulate the expression of a given target gene to any desired level
in a cell type-specific manner.
We next tested the use of these vectors in targeting endoge-
nous genes. We chose to analyze the tumor suppressor p53 and
the p65 subunit of the NFB transcription factor, both of which
have well characterized cellular phenotypes when down-
regulated. Decreased expression of p53 should compromise its
ability to induce the up-regulation of downstream targets such as
mdm2 and p21 in response to genotoxic stress (34). Similarly,
lowering the levels of p65 should cause down-regulation of IB
and IB proteins (34). IB is a transcriptional target of p65;
IB protein levels are stabilized by p65. Lentiviral vectors
containing shRNAs for both the p53 and p65 genes were
generated in both the LV-shRNA-WTGFP (Fig. 1D) and
LV-shRNA-OFF configurations (Fig. 1B). Mouse embryonic
fibroblasts were transduced with combinations of LV-shRNA-
WTGFP, LV-shRNA-OFF, and LV-CRE, as shown in Fig. 3
A and B. Coinfection of a fixed amount of LV-CRE (moi 700)
with increasing mois of LV-shp65-OFF (moi 50, 100, 200, and
400) led to a concomitant decrease of p65 (Fig. 3A, lanes 3–6).
This decrease of p65 led to reduced levels of both IB and IB
and also sensitized the cells to tumor necrosis factor -induced
apoptosis (Fig. 3B). Notably, the highest moi of LV-shp65-OFF
(moi  400) used in the absence of LV-CRE had no effect on
p65 activity (Fig. 3A, compare lanes 6 and 7). LV-shp65GFP
was used as a positive control in these experiments (Fig. 3A, lane
2). Similarly, coinfection of LV-CRE with increasing mois of
LV-shp53-OFF resulted in increased down-regulation of basal
and doxorubicin-induced p53 and its target genes p21 and mdm2
(Fig. 3C, lanes 4–7). The LV-shp53GFP used as a positive
control could efficiently reduce the level of doxorubicin-induced
p53 stabilization, whereas an equally high moi of LV-shp53-OFF
in the absence of LV-CRE had no effect on any of the three
genes tested (Fig. 3C, lane 8).
In summary, we have developed a lentiviral vector carrying an
siRNA-silencing cassette that is inactive until turned on by CRE
recombinase. Our results suggest that levels of expression of any
target gene can be manipulated by varying the mois of infection
with LV-CRE and L-shRNA-OFF, optimizing infection levels
depending on the gene target, the level of expression desired,
and ease of infection of the particular cell line involved. Two
reports describing CRE-inducible siRNA systems have recently
been published (35, 36). Our system couples RNA interference-
mediated silencing with the ability of lentiviral vectors to trans-
duce both dividing and nondividing cells, and used in combina-
tion with lentiviral transgenesis techniques, it will provide a rapid
and powerful approach to the study of gene function by gener-
ating localized, temporal, and tissue-specific knockdown of
specific targets. Use of CRE under the control of tissue-specific
promoters will allow precise dissection of signaling pathways
between distinct populations of cells in vitro and in vivo. In
particular, genes with embryonic lethal phenotypes can now be
tested for function by down-regulating the gene target in any cell
type, location, and developmental time frame, provided ade-
quate cell type-specific promoters are available.
We thank Kenneth Frimpong and Peter Welch of Invitrogen for
technical support. We also thank O. Singer, N. Tonnu, and N. Hoong for
technical support and critically reviewing the manuscript. G.T. is sup-
ported by an Institute of Molecular Medicine training grant (University
of California, San Diego). V.T. is supported by a career development
fellowship from the Leukemia and Lymphoma Society. I.M.V. is an
American Cancer Society Professor of Molecular Biology and is
supported in part by grants from the National Institutes of Health, the
Larry L. Hillblom Foundation, the Lebensfeld Foundation, the Wayne
and Gladys Valley Foundation, and the H. N. and Frances C. Berger
Foundation.
1. Wilson, J. A. & Richardson, C. D. (2003) Curr. Opin. Mol. Ther. 5, 389–396.
2. Zhao, L. J., Jian, H. & Zhu, H. (2003) Gene 316, 137–141.
3. Tomar, R. S., Matta, H. & Chaudhary, P. M. (2003) Oncogene 22, 5712–5715.
4. Sorensen, D. R., Leirdal, M. & Sioud, M. (2003) J. Mol. Biol. 327, 761–766.
5. Somasundaram, K. (2003) Cancer Biol. Ther. 2, 211–212.
6. Scherr, M., Battmer, K., Ganser, A. & Eder, M. (2003) Cell Cycle 2, 251–257.
7. Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L.,
Kopinja, J., Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B., et al.
(2003) Nat. Genet. 33, 401–406.
8. Matta, H., Hozayev, B., Tomar, R., Chugh, P. & Chaudhary, P. M. (2003)
Cancer Biol. Ther. 2, 206–210.
9. Katahira, T. & Nakamura, H. (2003) Dev. Growth Differ. 45, 361–367.
10. An, D. S., Xie, Y., Mao, S. H., Morizono, K., Kung, S. K. & Chen, I. S. (2003)
Hum. Gene Ther. 14, 1207–1212.
11. Miyagishi, M. & Taira, K. (2002) Nucleic Acids Res. 2, Suppl., 113–114.
12. Brummelkamp, T. R., Bernards, R. & Agami, R. (2002) Science 296, 550–553.
13. Barton, G. M. & Medzhitov, R. (2002) Proc. Natl. Acad. Sci. USA 99,
14943–14945.
14. Tiscornia, G., Singer, O., Ikawa, M. & Verma, I. M. (2003) Proc. Natl. Acad.
Sci. USA 100, 1844–1848.
15. Fjose, A., Ellingsen, S., Wargelius, A. & Seo, H. C. (2001) Biotechnol. Annu.
Rev. 7, 31–57.
16. Hannon, G. J. (2002) Nature 418, 244–251.
17. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl,
T. (2001) Nature 411, 494–498.
18. Paul, C. P., Good, P. D., Winer, I. & Engelke, D. R. (2002) Nat. Biotechnol. 20,
505–508.
19. Oliveira, D. M. & Goodell, M. A. (2003) Genesis 36, 203–208.
20. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S. & Khvorova,
A. (2004) Nat. Biotechnol. 22, 326–330.
21. Dirac, A. M. & Bernards, R. (2003) J. Biol. Chem. 278, 11731–11734.
22. Follenzi, A., Ailles, L. E., Bakovic, S., Geuna, M. & Naldini, L. (2000) Nat.
Genet. 25, 217–222.
23. Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D. &
Naldini, L. (1998) J. Virol. 72, 8463–8471.
24. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. & Verma, I. (2002) Cancer Cell
1, 493–503.
25. Allison, D. S. & Hall, B. D. (1985) EMBO J. 4, 2657–2664.
26. Kuhn, R. & Torres, R. M. (2002) Methods Mol. Biol. 180, 175–204.
27. Bark, C., Weller, P., Zabielski, J., Janson, L. & Pettersson, U. (1987) Nature
328, 356–359.
28. Das, G., Henning, D., Wright, D. & Reddy, R. (1988) EMBO J. 7, 503–512.
29. Goomer, R. S. & Kunkel, G. R. (1992) Nucleic Acids Res. 20, 4903–4912.
30. Lee, G. & Saito, I. (1998) Gene 216, 55–65.
31. Pfeifer, A., Brandon, E. P., Kootstra, N., Gage, F. H. & Verma, I. M. (2001)
Proc. Natl. Acad. Sci. USA 98, 11450–11455.
32. Schmidt, E. E., Taylor, D. S., Prigge, J. R., Barnett, S. & Capecchi, M. R. (2000)
Proc. Natl. Acad. Sci. USA 97, 13702–13707.
33. Levine, A. J. (1997) Cell 88, 323–331.
34. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. & Baltimore, D. (1995) Nature
376, 167–170.
35. Fritsch, L., Martinez, L. A., Sekhri, R., Naguibneva, I., Gerard, M., Van-
dromme, M., Schaeffer, L. & Harel-Bellan, A. (2004) EMBO Rep. 5, 178–182.
36. Kasim, V., Miyagishi, M. & Taira, K. (2003) Nucleic Acids Res. 3, Suppl.,
255–256.
Tiscornia et al. PNAS  May 11, 2004  vol. 101  no. 19  7351
G
EN
ET
IC
S
